timiperone and Vomiting

Topics: Administration, Oral; Adult; Antiemetics; Antipsychotic Agents; Butyrophenones; Cisplatin; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Vomiting

As we already reported, timiperone, a new neuroleptic agent of the butyrophenone group, has a strong antiemetic effect against cisplatin (CDDP)-induced emesis. With timiperone 6 mg/day p.o. from the day before undergoing CDDP therapy to the last day of the therapy, non-vomiting rate was 80%. The most unfavorable adverse effect of this regimen was extrapyramidal symptoms which appear in almost 100% of the patients aged under forty-five. In this study, we attempted to reduce the dose of timiperone and its adverse effect in combination with low-dose methylprednisolone (MPL). Seventeen cases of urological malignancies with a 5-day course of CDDP (15 approximately 25 mg/m2) including anticancer therapy were entered in this open trial. Four cases aged under forty-five were given timiperone 1.5 mg/day p.o. from the day before undergoing CDDP therapy with MPL 125 mg i.v. immediately before CDDP was administered. Thirteen cases aged over forty-five were given timiperone 3.0 mg/day p.o. with MPL given in the same way. Non-vomiting rates were 47 and 79%, respectively. Extrapyramidal symptoms were seen in two cases of both groups. It was concluded that timiperone 3.0 mg with MPL 125 mg has an antiemetic efficacy comparable to that of timiperone 6.0 mg but with less adverse effects.

Topics: Adult; Aged; Antiemetics; Basal Ganglia Diseases; Butyrophenones; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolone; Middle Aged; Nausea; Urologic Neoplasms; Vomiting

A new neuroleptic drug, Timiperone, is able to exert an antiapomorphine effect at doses smaller than cataleptogenic doses. Nineteen patients with urologic malignancy undergoing chemotherapy with cisplatin in combination with other agents were studied for the antiemetic efficacy of Timiperone. Six of 8 patients over 46 years old treated with Timiperone 6 mg/day p.o. from the day before undergoing DDP therapy to the last day of the therapy had no episode of vomiting and 2 patients had a few episodes of emesis (one and two episodes during 5 days of undergoing DDP, respectively). Five patients under 45 years old given Timiperone 6 mg/day by the same method had few episodes of vomiting, but suffered from extrapyramidal symptoms. Finally 6 patients undergoing DDP with Timiperone in combination with trihexyphenidyl suffered no symptoms of catalepsy but sometimes had mild vomiting episodes (1-4 times a day). We would like to propose that in antiemetic therapy with Timiperone for cisplatin-induced nausea and vomiting, a dose of 4.5 mg/day be given from two days before undergoing chemotherapy because of the cumulative effect of Timiperone.

Topics: Adult; Aged; Antiemetics; Butyrophenones; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Vomiting

Topics: Administration, Oral; Adult; Aged; Butyrophenones; Cisplatin; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Testicular Neoplasms; Uterine Neoplasms; Vomiting